Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Journal of Clinical Pharmacology

Volumn 56, Issue 5, 2016, Pages 637-645

  Chang, Ming ^a   Yu, Zhigang ^a   Shenker, Andrew ^a   Wang, Jessie ^a   Pursley, Janice ^a   Byon, Wonkyung ^b   Boyd, Rebecca A ^b   LaCreta, Frank ^a   Frost, Charles E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

Author keywords

anticoagulant; apixaban; pharmacodynamics; pharmacokinetics; renal impairment

Indexed keywords

APIXABAN; CREATININE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOMA; HEMATURIA; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NORMAL HUMAN; OPEN STUDY; PYURIA; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; AGED; BLOOD; CONTROLLED CLINICAL TRIAL; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CREATININE; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RENAL INSUFFICIENCY;

EID: 84964258745     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.633     Document Type: Article

References (40)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008; 133: 160S-198S.
2. Palareti G, Manotti C, D'Angelo A, et al., Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemostas. 1997; 78: 1438-1443.
3. Weitz JI, Hirsh J, Samama MM., New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 234S-256S.
4. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ., Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361: 594-604.
5. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375: 807-815.
6. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM., Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363: 2487-2498.
7. Connolly SJ, Eikelboom J, Joyner C, et al., Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.
8. Granger CB, Alexander JH, McMurray JJ, et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
9. Agnelli G, Buller HR, Cohen A, et al., Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799-808.
10. Agnelli G, Buller HR, Cohen A, et al., Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.
11. Bristol-Myers Squibb. Eliquis (apixaban tablets). Prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202155s009lbl.pdf. Accessed February 6, 2015.
12. Raghavan N, Frost CE, Yu Z, et al., Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37: 74-81.
13. Wang X, Mondal S, Wang J, et al., Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014; 14: 147-154.
14. Zhang D, He K, Herbst J, et al., Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013; 41: 827-835.
15. Frost C, Yu Z, Nepal S, et al., Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148]. J Clin Pharmacol. 2008; 48: 1132.
16. Vakkalagadda B, Frost C, Wang J, et al., Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract 143]. J Clin Pharmacol. 2009; 49: 1124.
17. Cockcroft DW, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
18. Food and Drug Administration. Guidance for Industry: Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. 1998. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072127.pdf. Accessed July 13, 2015.
19. Nilsson-Ehle P, Grubb A., New markers for the determination of GFR: iohexol clearance and cystatin C serum concentration. Kidney Int Suppl. 1994; 47: S17-S19.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
21. Levey AS, Greene T, Kusek J.W., Beck GL,. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000; 11: 155A.
22. Pursley J, Shen JX, Schuster A, et al., LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis. 2014; 6: 2071-2082.
23. Farthing D, Sica DA, Fakhry I, et al., Simple HPLC-UV method for determination of iohexol, iothalamate, p-aminohippuric acid and n-acetyl-p-aminohippuric acid in human plasma and urine with ERPF, GFR and ERPF/GFR ratio determination using colorimetric analysis. J Chromatogr B Anal Technol Biomed Life Sci. 2005; 826: 267-272.
24. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500162133.pdf. Accessed July 29, 2015.
25. Food and Drug Administration. Guidance for Industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labelling. 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf. Accessed May 6, 2011.
26. Du Bois D, Du Bois EF,. Tenth paper a formula to estimate the approximate surface area, height and weight be known. Arch Intern Med (Chicago). 1916; 17: 863-871.
27. Barnes KJ, Rowland A, Polasek TM, Miners JO., Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014; 70: 1097-1106.
28. Dreisbach AW, Lertora JJ., The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008; 4: 1065-1074.
29. Wang X, Song Y, Tirucherai G, et al., Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev. 2012; 1: 175-229.
30. Frost C, Nepal S, Barrett Y, LaCreta F., Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban. J Thromb Haemostas. 2009; 7:PP-MO-407.
31. Manzano-Fernandez S, Andreu-Cayuelas JM, Marin F, et al., Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2015; 68: 497-504.
32. Barrett YC, Wang Z, Frost C, Shenker A., Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104: 1263-1271.
33. Cook DJ, Douketis J, Arnold D, Crowther MA., Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Curr Opin Pulm Med. 2009; 15: 455-462.
34. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D., Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56: 2214-2219.
35. Muntner P, He J, Hamm L, Loria C, Whelton PK., Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745-753.
36. Kearon C, Akl EA, Comerota AJ, et al., Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e419S-e494S.
37. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE., Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009; 43: 1064-1083.
38. Limdi NA, Limdi MA, Cavallari L, et al., Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010; 56: 823-831.
39. Hohnloser SH, Hijazi Z, Thomas L, et al., Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012; 33: 2821-2830.
40. Eikelboom JW, Connolly SJ, Gao P, et al., Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012; 21: 429-435.